| 查看: 573 | 回复: 3 | |||
[交流]
西替利嗪在儿童用药的主要风险是什么？
|
|
西替利嗪用于儿童，不同资料说法不一：包括“不推荐用于6岁以下儿童”，“不推荐用于12岁以下儿童”，“2岁以下儿童禁用”，“可用于儿童及妊娠或哺乳的妇女”不一而足。 目前权威的说法是？ 西替利嗪在儿童用药的主要风险是什么？ 希望有最新资料的站友给予解释 |
回复此楼» 猜你喜欢
281求调剂（0805）
已经有8人回复
-
环境领域全国重点实验室招收博士1-2名
已经有3人回复
-
材料专硕306英一数二
已经有10人回复
-
301求调剂
已经有6人回复
-
一志愿天津大学化学工艺专业（081702）315分求调剂
已经有7人回复
-
302求调剂
已经有6人回复
-
26博士申请
已经有3人回复
-
268求调剂
已经有3人回复
-
311求调剂
已经有10人回复
-
被我言中：新模板不强调格式了，假专家开始管格式了
已经有4人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 转：用创新承载梦想--扬子江药业致力新品名品开发研制巡礼
已经有15人回复
- 【转帖】强生制药双阴影：召回局未了，质量门添忧
已经有0人回复
» 抢金币啦！回帖就可以得到:
-
西湖大学工学院智能微型机器人实验室博士后招聘启事
+4/228
-
南京医科大学生殖医学与子代健康国重实验室-董飞宏课题组-学术硕士招生
+1/97
-
物理学 调剂
+1/80
-
博士后出站经验请教
+1/78
-
【代人发帖勿站内信】【成都征男友】89年未婚博士漂亮女孩
+1/71
-
上海交大化院功能大分子团队招2026年硕士、联培、博士后
+1/38
-
2026年重庆工商大学管理科学与工程专业学术硕士招生调剂，风景总在柳暗花明处
+1/36
-
中科院生态环境研究中心国重实验室招聘客座研究生1-2名
+1/31
-
新加坡国立大学药学系化学生物学课题组招PhD
+1/18
-
南京林业大学-国家级青年人才团队 招2026级申请考核制博士（合成化学、植物化学方向）
+1/14
-
招收化工与材料学科点研究生
+1/13
-
南京医科大学-膜蛋白结构与功能课题组-招收2026级博士研究生
+1/11
-
【全奖招生】北师港浸大ESLAS实验室招收密码工程/网络安全/计算机视觉博士/博士后
+1/10
-
26年申博自荐-计算机视觉
+1/7
-
上海师范大学化学与材料科学学院任新意副研究员招收调剂学生3-4名（有机化学专业）
+1/5
-
东北林业大学（211，双一流）宋老师课题组招收高分子、化学、复合材料等方向研究生
+1/4
-
博后即将出站，求稳定的教职
+1/3
-
分离分析杰青课题组诚招科研人员
+1/3
-
上海交通大学化学化工学院张智涛课题组诚聘博士后
+1/2
-
西安交通大学生命学院智能化诊疗装备研究中心2026年博士生招生
+1/1
2楼2011-07-13 14:49:57
3楼2011-07-13 21:28:14
★
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
|
以下是国外网站的资料，显示对6个月以上儿童进行过安全性评价，应该可以使用。 国外上市的有片剂、糖浆剂和咀嚼片。 ZYRTEC (cetirizine) can be taken without regard to food consumption. ZYRTEC (cetirizine) is available as 5 mg and 10 mg tablets, 1 mg/mL syrup, and 5 mg and 10 mg chewable tablets which can be taken with or without water. Adults and Children 12 Years and Older: The recommended initial dose of ZYRTEC (cetirizine) is 5 mg or 10 mg per day in adults and children 12 years and older, depending on symptom severity. Most patients in clinical trials started at 10 mg. ZYRTEC (cetirizine) is given as a single daily dose. The time of administration may be varied to suit individual patient needs. Children 6 to 11 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 6 to 11 years is 5 mg or 10 mg once daily depending on symptom severity. The time of administration may be varied to suit individual patient needs. Children 2 to 5 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 2 to 5 years is 2.5 mg (? teaspoon) syrup once daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoon syrup once a day or one ? teaspoon syrup given every 12 hours, or one 5 mg chewable tablet once a day. Children 6 months to <2 years: The recommended dose of ZYRTEC (cetirizine) syrup in children 6 months to 23 months of age is 2.5 mg (? teaspoon) once daily. The dose in children 12 to 23 months of age can be increased to a maximum dose of 5 mg per day, given as ? teaspoon (2.5 mg) every 12 hours. Syrup is recommended for children under the age of 2 years. Pediatric Use: The safety of ZYRTEC (cetirizine) has been demonstrated in pediatric patients aged 6 months to 11 years. The safety of ZYRTEC (cetirizine) , at daily doses of 5 or 10 mg, has been demonstrated in 376 pediatric patients aged 6 to 11 years in placebo-controlled trials lasting up to four weeks and in 254 patients in a non-placebo-controlled 12-week trial. The safety of cetirizine has been demonstrated in 168 patients aged 2 to 5 years in placebo-controlled trials of up to 4 weeks duration. On a mg/kg basis, most of the 168 patients received between 0.2 and 0.4 mg/kg of cetirizine HCl. The safety of cetirizine in 399 patients aged 12 to 24 months has been demonstrated in a placebo-controlled 18-month trial, in which the average dose was 0.25 mg/kg bid, corresponding to a range of 4 to 11 mg/day. The safety of ZYRTEC (cetirizine) syrup has been demonstrated in 42 patients aged 6 to 11 months in a placebo-controlled 7-day trial. The prescribed dose was 0.25 mg/kg bid, which corresponded to a mean of 4.5 mg/day, with a range of 3.4 to 6.2 mg/day. The effectiveness of ZYRTEC (cetirizine) for the treatment of allergic rhinitis and chronic idiopathic urticaria in pediatric patients aged 6 months to 11 years is based on an extrapolation of the demonstrated efficacy of ZYRTEC (cetirizine) in adults with these conditions and the likelihood that the disease course, pathophysiology and the drug's effect are substantially similar between these two populations. Efficacy is extrapolated down to 6 months of age for perennial allergic rhinitis and down to 2 years of age for seasonal allergic rhinitis because these diseases are thought to occur down to these ages in children. The recommended doses for the pediatric population are based on cross-study comparisons of the pharmacokinetics and pharmacodynamics of cetirizine in adult and pediatric subjects and on the safety profile of cetirizine in both adult and pediatric patients at doses equal to or higher than the recommended doses. The cetirizine AUC and Cmax in pediatric subjects aged 6 to 23 months who received a mean of 2.3 mg in a single dose, and in subjects aged 2 to 5 years who received a single dose of 5 mg of cetirizine syrup and in pediatric subjects aged 6 to 11 years who received a single dose of 10 mg of cetirizine syrup were estimated to be intermediate between that observed in adults who received a single dose of 10 mg of cetirizine tablets and those who received a single dose of 20 mg of cetirizine tablets. The safety and effectiveness of cetirizine in pediatric patients under the age of 6 months have not been established. Last reviewed on RxList: 5/17/2007 This monograph has been modified to include the generic and brand name in many instances. 别人的回复，贴到这，与同道共享 |
4楼2011-07-14 10:35:31
